Skip to content

Vaping Cessation Using the Ottawa Model for Smoking Cessation Among E-Cigarette Users

Vaping Cessation Using the Ottawa Model for Smoking Cessation Among E-Cigarette Users: A Pilot RCT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06164678
Acronym
VC-OMSC
Enrollment
180
Registered
2023-12-11
Start date
2024-07-11
Completion date
2026-12-01
Last updated
2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco Smoking, Vaping

Brief summary

This study aims to determine if a standardized approach including counselling and Nicotine Replacement Therapy (NRT) can help e-cigarette users quit vaping. Current e-cigarette users will be randomly assigned to either to counselling and NRT or counselling only group. Self-reported rates of vaping cessation will be measured throughout the year in both groups. The use of e-cigarettes has grown substantially among non-smokers, particularly among youth and young adults. These devices deliver high levels of nicotine, far greater than is possible with conventional cigarettes. Currently, they are not approved for smoking cessation or any purpose by Health Canada. Nonetheless, there is some evidence that e-cigarettes may be of assistance in smoking cessation. Conversely, there is evidence that using cigarettes and e-cigarettes together may result in increased cigarette consumption. E-cigarette use among youth also serves as a gateway to regular use of conventional cigarettes. Clinicians and patients are seeking guidance on vaping cessation. However, to date, there are no strong evidence-based interventions to support e-cigarette users in quitting. NRT is approved for smoking cessation by Health Canada. However, it is not approved for vaping cessation and thus its use to support e-cigarette users to quit by managing their nicotine withdrawal is considered "off-label". This represents a significant gap and opportunity, which this project will address. The study hypothesizes that the OMSC approach, which includes the use of nicotine replacement therapy, will result in higher rates of vaping cessation compared to usual care. Participants will all complete an initial counselling session to discuss vaping cessation and receive tips to help achieve cessation. They will all be asked to track their smoking/vaping behaviour and the amount of tobacco in their e-cigarette for 7 days. After 7 days, all participants will be randomly put into one of two groups (either the intervention or control group). They will have follow-up assessments with the research team at 1, 3, 6 and 12 months.

Interventions

BEHAVIORALOMSC

The OMSC program uses a counselling approach to assist clients with tobacco cessation. If required, nicotine replacement therapy may be offered.

Sponsors

Ottawa Heart Institute Research Corporation
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Investigator, Outcomes Assessor)

Masking description

A blinded member of the research team will complete all follow-up assessments

Intervention model description

Participants are randomized 1:1

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* \>18 years of age or older * Ontario resident * Ability to speak English or French * Regular use of e-cigarette (vaping at least once per week for the past four weeks)

Exclusion criteria

* Cognitive impairment or acute psychiatric illness that would alter their ability to participate * Being institutionalized at a retirement home, nursing home or long-term care facility * Participating in another smoking or vaping cessation program * Allergy or intolerance to NRT

Design outcomes

Primary

MeasureTime frameDescription
Vaping Cessationbaseline to 3 months7-day point prevalence of vaping cessation measured at 3-months.

Secondary

MeasureTime frameDescription
Continuous Abstinence1-day, 7-day, 1-month, 3-month, 6-month, and 12-month from baseline dateContinuous abstinence rates at 1-day, 7-day, 1-month, 3-month, 6-month, and 12-month follow up.
Successful cessation12 month assessmentSelf-reported cessation will be measured by a self-administered salivary cotinine test.

Countries

Canada

Contacts

PRINCIPAL_INVESTIGATORHassan Mir, MD

Ottawa Heart Institute Research Corporation

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 9, 2026